Lynparza For Pancreatic Cancer: ODAC's Narrow Support Leaves US FDA In Quandary

 
• By Michael Cipriano

The Oncologic Drugs Advisory Committee voted 7-5 in favor of AstraZeneca's Lynparza for the treatment of gBRCAm pancreatic cancer, leaving the FDA in a dilemma over how much data to require.

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers